The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with ...
Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of ...
The US Food and Drug Administration granted full approval to mirvetuximab soravtansine-gynx (Elahere) for adults with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian ...
The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, ...
A new wave of cancer treatments is looking promising for the future of oncologic care. The ovarian cancer drug RC88, which is made by the Chinese biopharmaceutical company RemeGen, received FDA ...
OSLO, Norway--(BUSINESS WIRE)--Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a ...
R-DXd targets CDH6 in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers, showing a 46% objective response rate in a phase 1 trial. FDA breakthrough therapy designation aims to ...
Effect of nilotinib on cell proliferation and migration of ovarian cancer cells alone and in combination with standard chemotherapy. Background: Advances in laparoscopic surgery have allowed a ...
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback